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Background:To evaluate the performance of Framinghampredictions of cardiovascular disease (CVD) risk corrected
for the competing risk of non-CVDdeath, in an independent European cohort of older individuals and subsequently
extend the predictions by disentangling CVD into coronary heart disease (CHD) and stroke separately.
Methods:We used the Rotterdam Study data, a prospective cohort study of individuals aged 55 years and older
(N = 6004), to validate the Framingham predictions of CVD, deﬁned as ﬁrst occurrence of myocardial infarction,
coronary death or stroke during 15 years of follow-up, corrected for the competing risk of non-CVD death.We sub-
sequently estimated the risks of CHD and stroke separately, and used the sum as a predictor for the total CVD risk.
Calibration plots and c-statistics were used to evaluate the performance of the models.
Results: Performance of the Framinghampredictionswas good in the low- to intermediate risk (≤30%, 15-year CVD
risk) (17.5% observed vs. 16.6% expected) but poorer in the higher risk (N30%) categories (36.3% observed vs. 44.1%
expected). The c-statistic increased from 0.66 to 0.69 after reﬁtting. Separately estimating CHD and stroke revealed
considerable heterogeneity with regard to the contribution of CHD and stroke to total CVD risk.
Conclusions: Framingham CVD risk predictions perform well in the low- to intermediate risk categories in the Rot-
terdam Study. Disentangling CVD into CHD and stroke separately provides additional information about the indi-
vidual contribution of CHD and stroke to total individual CVD risk.© 2014 Elsevier Ireland. Ltd All rights reserved.1. Introduction
The use of risk scores as tools to predict cardiovascular disease (CVD)
has been widely advocated in primary prevention [1–5]. Guidelines on
the prevention of CVD incorporate risk scores in order to make treat-
ment recommendations [6,7]. However, older individuals are at high
risk of death due to other causes than CVD. Currently recommended
Framingham risk scores tend to overestimate CVD risk in an older pop-
ulation, as non-CVD mortality competes with CVD events [8], and the
competing risk is not taken into account in these models.
Although traditional Framingham risk scores have been successfully
externally validated in some other populations, recalibration was often
necessary to obtain valid estimates [9]. The 30-year CVD risk functions MC, Dr. Molenwaterplein 40,
0, 3000 CA, Rotterdam, The
57.
nink).
td All rights reserved.developed by Pencina et al. [3], based on the Framingham Offspring co-
hort was developed to address the need for both long-term CVD predic-
tion and taking into account the competing risk of non-CVD death. The
function estimates total CVD as the combination of coronary heart dis-
ease (CHD) and stroke. In contrast with more traditional risk scores,
this Framingham risk function has not been externally validated.
Both CHD and stroke contribute to the risk of total CVD, but can be
regarded as different clinical events, for which different risk factors
have been identiﬁed [5,10]. As the prevention of both events sometimes
is associated with different recommendations [11], disentangling the
risk of total CVD into both components could provide clinicians with
useful additional information for treatment management.
Therefore, using 15-year follow-up data from the participants of the
Rotterdam Study Cohort, a population based cohort study of elderly in-
dividuals [12], we aimed to 1) evaluate the performance of Framingham
predictions of cardiovascular disease (CVD) risk corrected for the
competing risk of non-CVD death, in an independent European cohort
and 2) update the predictions by disentangling CVD into coronary
heart disease (CHD) and stroke separately.
Table 1
Baseline characteristics for the6004RotterdamStudy participants included in the analysis.
Risk factor
Age, years, median (IRQ) 68 (62–75)
Men, n (%) 2251 (37.5)
Systolic BP mm Hg, median (IQR) 138 (123–153)
Missing data, n (%) 52 (1.0%)
Antihypertensive drugs, n (%) 654 (10.9%)
Missing data, n (%) 4 (0.0%)
Anti-thrombotic drugs, n (%) 195 (3.2%)
Missing data, n (%) 4 (0.0%)
Cholesterol lowering drugs, n (%) 108 (1.8%)
Missing data, n (%) 4 (0.0%)
Current smoking, n (%) 1345 (22.4%)
Missing data, n (%) 162 (2.7%)
Total cholesterol
mg/dL, median (IRQ) 255.8 (224.8–286.8)
Missing data, n (%) 77 (1.3%)
HDL cholesterol
mg/dL, median (IRQ) 50.4 (42.6–62.0)
Missing data, n (%) 103 (1.7%)
Diabetes mellitus, n (%) 618 (10.3%)
Missing data, n (%) 406 (6.7%)
IQR: interquartile range.
Fig. 1. Calibration plot, showing predicted and observed 15-year risk of CVD for eachdecile
of predicted 15-year CVD risk, based on the original Framingham CVD function [3] (model
1, left) and the recalibrated score by adjusting baselinehazards of CVD and non-CVDdeath
(model 2, right).
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2.1. Study population
Of the 7983 respondents originally included in the Rotterdam Study, 6871 individuals
both visited the research center and signed an informed consent. Of those, 6004 individ-
uals had no history of CHD and stroke. Individuals have been followed in an ongoing effort
from 1990 onwards and consisted of regular examinationswith interviews and direct dig-
ital linkage to medical ﬁles from the general practitioners working in the research area,
death registries and other available medical sources, ensuring accurate follow-up of fatal
and non-fatal CVD events and cause-speciﬁcmortality [12]. Themedical records of nursing
home were also evaluated. At baseline, participants were interviewed at home by trained
research assistants using a computerized questionnaire. Baseline data included informa-
tion on the current health status, history of cardiovascular disease, current medication
use, and cardiovascular risk factors. Subsequently, the participants were invited to the re-
search center in order to obtain measurements on cardiovascular risk factors, including
bodymass index, blood pressure, total cholesterol, high-density lipoprotein (HDL) choles-
terol, and non-fasting glucose level. All subjects gave written informed consent, and the
study was approved by the medical ethics committee of Erasmus MC.
2.2. Assessment of risk factors
Details of the assessment of CVD risk factors and medical history in the Rotterdam
Study are described into more detail elsewhere [13]. In short, participants were
categorized with regard to current smoking status (nonsmoker deﬁned as never smoked
or abstinence for at least 2 years). Systolic blood pressure was calculated as the mean of
two measurements [14]. Serum total and HDL cholesterol levels were determined by an
automated enzymatic procedure. Diabetes mellitus was deﬁned as current use of anti-
diabetic medication and/or a random or post-load serum glucose ≥200 mg/dL
(11.1 mmol/L).
2.3. Clinical end points
Events were classiﬁed using ICD-10 codes. We focused on ‘hard’ CVD as the outcome
of interest, deﬁned as the composite of hard CHD (consisting of myocardial infarction and
coronary death and stroke, both fatal and non-fatal). The deﬁnition of coronary heart dis-
easemortality,more speciﬁcally the out-of hospitalmortality attributable to CVD, changed
slightly during follow-up from 2003 onwards [13], to enhance comparability with other
large CVD cohort studies. In order to adjust for the competing risk of non-CVD death, as
was done in the Framingham model, we deﬁned non-CVD mortality as any death due to
causes other than from CVD events. All events were independently adjudicated by two re-
search physicians. Consensus was met in a separate session and if necessary medical spe-
cialists were consulted. We used follow-up information available until January 1, 2007
leading to a maximum follow-up duration of 17 years for an individual.
2.4. Statistical analysis
Complete risk proﬁles were available in 5436 of the 6004 individuals used in the anal-
ysis. We imputed missing values of systolic blood pressure, total and HDL cholesterol, di-
abetes status, antihypertensive medication use and current smoking status of the
Rotterdam Study participants with imputation models that included all risk factors —
age, sex, systolic blood pressure, use of antihypertensives, smoking, diabetes, total and
HDL cholesterol, and the log cumulative hazard for hard CVD [15]. All continuous variables
were log-transformed by taking the natural logarithm in correspondence with the Fra-
mingham model, and truncated at their 1st and 99th percentile. Fifteen-year risks of
hard CVD and competing non-CVD death for the 6004 Rotterdam Study participants
were calculated using the baseline survival at 15 years of both events as reported by
Pencina et al. [3], and the linear predictors of CVD and non-CVD death calculated using
the published hazard rate ratios (model 1).
A standard Cox model may provide biased estimates of absolute long-term risk be-
cause it treats those who die of a non-CVD cause as eligible for the development of a
CVD event. We therefore used the model proposed by Rosthoj et al. and Putter et al.
[16,17], which is the same statistical model as Pencina et al. used in the 30-year predic-
tions of CVD. This model calculates the cumulative incidence of CVD per individual, by
summation of the cause-speciﬁc hazard multiplied by the survival of the CVD event and
the competing non-CVD death event at each failure time.
We compared the average predicted 15-year risk of CVD, with the average observed
outcome in the Rotterdam Study participants [18]. We then recalibrated the Framingham
CVD model by updating the 15-year baseline survival of CVD and non-CVD death as well,
with the survival as observed in the Rotterdam Study (model 2). To check whether the
overall effect of the risk factors based on the Framingham data is valid for the Rotterdam
population, we recalibrated model 2, by allowing for a different effect for the slope of
the linear predictors of CVD and non-CVD death (model 3). Subsequently, we reﬁtted
the Framingham CVD model for CVD and non-CVD death, and compared the coefﬁcients
of the risk factors found by ﬁtting the model in the Rotterdam population data, with the
original ones published by Pencina et al. (model 4). Finally, we reﬁned the original
model by estimating the hazards of hard CHD and stroke separately. This was done as
theweights assigned to different risk factors and the shape of the lifetime hazard function
may be different for CHD and stroke [2]. Accounting for this difference could potentially
further improve CVD risk classiﬁcation. We therefore ﬁtted three cause-speciﬁc Cox
models, one for hard CHD, one for stroke and one for the competing event deﬁned asdeath from any cause other than MI, coronary disease or stroke (model 5). We subse-
quently calculated the cumulative incidences for hard CHD and stroke, and added the
cumulative incidences of hard CHD and stroke to obtain the estimate for (total) CVD.
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justed for the competing risks by setting the failure time of an individual who experienced
the competing event to inﬁnity. In practice, thiswasdonebyadding1 to themaximumfol-
low-up time i.e. 15 years [8]. Subsequently, calibration of CVDwas assessed by calibration
plots, comparing predicted risks of CVD with observed incidences, per decile of predicted
CVD risk, for each of the ﬁve models. We used deciles of predicted CVD risk to make the
categories consistent across the plots. The observed incidenceswere adjusted for compet-
ing risks, using the R ‘CumInc’ function, which is included in the R ‘mstate’ library [17].
An Excel risk score calculator was constructed to provide clinicians with a tool to es-
timate the cumulative incidences of CHD, stroke and CVD conditional on an individuals'
risk proﬁle and is available in the online data supplement. All analyses were performed
using SPSS version 19 (SPSS forWindows) and R version 2.14 (R Foundation for Statistical
Computing, Vienna, Austria).
3. Results
Baseline characteristics of the 6004 Rotterdam Study participants
used in this analysis are presented in Table 1. During 15 years of fol-
low-up, 539 (ﬁrst) hard CHD, 630 (ﬁrst) stroke and 1719 competing
non-CVD deaths occurred in these individuals.
3.1. Calibration
Calibration of the Framingham CVD model was found to be good in
the low- to intermediate risk (≤30%, 15-year risk) categories (17.5% ob-
served vs. 16.6% expected) but relatively poor in the higher risk (N30%,
15-year risk) categories (36.3% observed vs. 44.1% expected) (Fig. 1).Fig. 2.Calibration plot, showing predicted and observed15-year risk of CVD for each decile
of predicted 15-year CVD risk, based on the reﬁtted function (model 4, left) and reﬁtting
the CVD and non-CVD death function, by separately analyzing CHD and stroke (model 5,
right).Updating the baseline hazards and slope of the linear predictors of
CVD and non-CVD death improved calibration in the higher risk catego-
ries slightly (36.2% observed, vs. 42.3% expected) but overestimation
remained. After reﬁtting the CVD risk function in the Rotterdam data,
calibration improved substantially (low to intermediate categories:
16.6% observed vs. 16.6% expected; higher risk categories: 39.3% ob-
served vs. 38.9% expected). Separately estimating CHD and stroke
improved calibration even somewhat further (low to intermediate cat-
egories: 16.7% observed vs. 16.6% expected; higher risk categories:
38.8% observed vs. 38.8% expected) (Fig. 2). Calibration of the compet-
ing non-CVD death event, evaluated by plotting the observed risk of
non-CVD death vs. predicted per decile of CVD risk, revealed that the
risk of non-CVD is underestimated for the original Framingham CVD
function for all categories of individuals, and increased with CVD risk.
After reﬁtting, calibration of non-CVD mortality improved as well
(Fig. 3).3.2. Discrimination
C-statistics for the FraminghamCVD risk function applied to the Rot-
terdamStudypopulation for the prediction of 15-year CVD riskwas 0.66
and 0.68 after reﬁtting the Framingham CVD risk function in the Rotter-
dam Study population. Estimating the hazard of CVD separately for CHD
and stroke and using the sum as an estimate for total CVD, did notFig. 3. Calibration plot, showing predicted and observed 15-year risk of competing non-
CVD death for each decile of predicted 15-year CVD risk, based on the original
Framingham CVD function [3] (model 1, left) and after reﬁtting the CVD and non-CVD
death function in the Rotterdam Study data (model 4, right).
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decimal points.3.3. Beta coefﬁcients
Reﬁtting the Framingham CVD risk function in the Rotterdam data
led to differences in beta coefﬁcients compared to the original ones pub-
lished by Pencina et al. (Table 2a). For CVD, the log of age was found to
have a stronger effect on CVD whereas sex, the log of systolic blood
pressure, log of total and HDL cholesterol, current smoking status and
diabetes were signiﬁcantly less strong. For the competing risk of non-
CVD death, the log of age was also found to have a signiﬁcantly stronger
effect, whereas the log of systolic blood pressure, current smoking and
diabetesmellitus had a less strong effect (Table 2b). Separately estimat-
ing the hazards CHD and stroke, resulted in different beta coefﬁcients
for both events compared to estimating the hazard of CVD as a
combined endpoint (Table 2c).3.4. Fifteen-year risk of CHD, stroke and CVD
To illustrate the effect of different individual risk proﬁles on CVD risk
and on the mixture of CHD and stroke, the cumulative incidences of
CHD, stroke and CVDwere plotted for a 15-year period for 4 individuals
(Fig. 4a–d). For individual a and b, stroke was the major component of
CVD. The opposite was true for individuals c and d.Table 2
Coefﬁcients for the Framingham CVD risk function, for 15-year CVD and non-CVD competing d
point (A, model 4), competing non-CVD death (B, model 4), and CHD and stroke separately (C
A
CVD Reﬁtted
Coefﬁcient p-valu
Male sex 0.44 b0.000
Natural logarithm of age 5.28 b0.000
Natural logarithm of systolic blood pressure 1.68 b0.000
Natural logarithm of serum total cholesterol 0.24 0.46
Natural logarithm of serum HDL cholesterol −0.49 b0.000
Current smoking 0.33 b0.000
Use of antihypertensives 0.23 0.004
Diabetes mellitus 0.46 b0.000
B
Non-CVD death Reﬁtted
Coefﬁcient p-valu
Male sex 0.37 b0.001
Natural logarithm of age 8.49 b0.001
Natural logarithm of systolic blood pressure 0.28 0.11
Natural logarithm of serum total cholesterol −0.92 b0.001
Natural logarithm of serum HDL cholesterol −0.12 0.24
Current smoking 0.58 b0.001
Use of antihypertensives 0.05 0.56
Diabetes mellitus 0.19 0.01
C
CHD
Coefﬁcient p-valu
Male sex 0.64 b0.000
Natural logarithm of age 5.89 b0.000
Natural logarithm of systolic blood pressure 1.0006 b0.000
Natural logarithm of serum total cholesterol 0.97 b0.000
Natural logarithm of serum HDL cholesterol −0.91 b0.000
Current smoking 0.27 0.0028
Use of antihypertensives 0.39 b0.000
Diabetes mellitus 0.51 b0.000
Original: coefﬁcients reported by Pencina et al. [3].4. Discussion
Our analyses show that the Framingham CVD risk predictions per-
form reasonably well in predicting in the relatively older Rotterdam
population for individuals at low to intermediate risk. For the higher
risk categories, recalibration by reﬁtting the function in the Rotterdam
Study population was required to obtain valid estimates. Disentangling
CVD into CHD and stroke separately revealed considerable heterogene-
ity with regard to the contribution of CHD and stroke to the total risk of
CVD.
To our knowledge, this is the ﬁrst attempt to validate this Framing-
ham CVD risk function corrected for competing death in another popu-
lation. Previous studies on the validity of Framingham risk functions in
the Rotterdam Study focused on 10-year CHD and stroke separately
[14,19] and found predictive performance to be reasonable in the
lower risk categories for both events, but recalibration was necessary
for the apparent overestimation in the higher risk categories. In the cur-
rent analysis we extended the previous work by incorporating a longer
period of follow-up and made adjustments for competing risks. In ac-
cordance with the earlier ﬁndings for 10-year CHD and stroke, we
found that recalibration was especially important in the higher CVD
risk categories.
Our study bears some limitations. First, the weights of the risk
factors in the original Framingham CVD risk function were estimated
over a 30-year period, whereas we validated the risk function for a 15-
year period. If the hazard ratios of the risk factors included in the
Framingham function would change over time, this could contributeeath in the Rotterdam Study data, evaluating a reﬁtted function for CVD as combined end-
, model 5).
Original
e in reﬁtted model Coefﬁcient p-value reﬁtted vs. original
1 0.55 0.08
1 2.28 b0.001
1 2.00 0.11
1.48 b0.001
1 −0.88 0.002
1 0.70 b0.001
0.39 0.05
1 0.91 b0.001
Original
e Coefﬁcient p-value reﬁtted vs. original
0.48 0.07
3.531 b0.001
1.43 b0.001
0.01 b0.001
0.09 0.042
0.97 b0.001
0.12 0.34
0.45 b0.001
Stroke
e Coefﬁcient p-value
1 0.12 0.2
1 6.09 b0.0001
1 2.06 b0.0001
1 −0.76 0.001
1 −0.07 0.65
0.35 b0.0001
1 0.22 0.06
1 0.39 b0.0001
Fig. 4. Individual predictions for 4 individuals: (a) 70-year oldwoman, smoker, systolic bloodpressure of 103, total (HDL) cholesterol 4.1 mmol/L 1.5, treated for hypertension; (b) 70-year
oldman, systolic blood pressure of 132, total (HDL) cholesterol 5.0 mmol/L 1.80, diabetic; (c) 56-year oldman, systolic blood pressure of 124, total (HDL) cholesterol 6.4 mmol/L 0.9; and
(d) 65-year old woman, systolic blood pressure of 129, total (HDL) cholesterol 6.7 mmol/L 0.9, treated for hypertension.
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the original Framingham function, Pencina et al. did not ﬁnd evidence
for the hazard rate ratios to be time-dependent, which makes different
hazard rate ratios for different time-horizons less likely [3]. From a clin-
ical point of view, a 15-year risk is probably of greater interest in older
individuals due to the shorter life expectancy and the potential effect
of co-morbidities and competing causes of death. Second, when sepa-
rately analyzing CHD and stroke, we used the same set of risk factors.
A further improvement in predictive performance could be expected if
we would allow for a different set of risk factors for both events and
competing events respectively. Third, as with all validity studies that
use external data from other cohorts, our studywas limited bymarginal
differences in outcome classiﬁcation. In order to enhance comparability
with other large CVD cohort studies, the classiﬁcation of coronary heart
diseasemortalitywas slightlymodiﬁed from 2003 onward, according to
standards that have served as a basis for the endorsed international case
deﬁnition for out-of-hospital CHD mortality in epidemiologic studies
[13], and adjusted the baseline hazard function in the current analysis.
Fourth, some individuals were using CVD protective drugs at baseline.
Ideally these individuals should be excluded from the analysis, but its
impact on results would be limited given that only few individuals
were using them. Furthermore, including these individuals in the anal-
ysis is in line with almost all other established risk scores [20]. Fifth,
correcting for initiation of CVD protective drugs during follow-up
could address the effect of treatment drop-ins. However, the same re-
view of established CVD risk scores [20] revealed that correcting fortreatment drop-ins is generally not accounted for, and follow-up
examinations of the Rotterdam Study population showed that statin
use was quite limited during later years [21].
Sixth, we did not evaluate the inclusion of novel risk factors, which
might further contribute to improvement in risk classiﬁcation.
As the Framingham population was younger on average than the
Rotterdam Study participants, we expected the baseline hazard of CVD
to be higher in the Rotterdam data. However, we observed that the Fra-
mingham function overestimated CVD risk, especially in the higher risk
strata. Part of this overestimation could be explained by the fact that the
Framingham function at the same time underestimated the risk of the
competing non-CVDdeathwhich is of particular importance in older in-
dividuals. Underestimation of the competing event results in a higher
predicted risk of the CVD event [8]. After adjusting the baseline hazards
for both the CVD event and the competing risk of non-CVD death, the
overestimation of CVD risk diminished substantially.
The hazard rate ratios of the risk factors were sometimes different in
magnitudes and signiﬁcance of the effects from the ones reported by
Pencina et al. [3]. Our observation that total cholesterol (in the presence
of other factors) did not appear a signiﬁcant predictor for CVD in the
Rotterdam data was supported by earlier analyses from Bos et al. in
the Rotterdam Study [22,23]. They found that serum cholesterol has a
protective effect on stroke, whereas HDL cholesterol has no signiﬁcant
effect. This is similar to what we found when we analyzed the hazard
of stroke separately from CHD. This could explain the non-signiﬁcant
effect for serum total cholesterol on total CVD in our analysis, as the
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stroke and CHD separately. The difference in coefﬁcients for age can
be partly explained by the log-transformation (log), together with the
older age of the Rotterdam Study cohort compared to Framingham.
The increase from log 70 years to log 71 years, a one unit increase on
the age scale, is smaller than the log increase from 40 to 41. This implies
that the coefﬁcient for age in the Rotterdamdata should compensate for
these smaller increments in the log-transformed risk factor.
We demonstrated that estimating the hazards for CHD and stroke
separately allows for the simultaneous prediction of the risks of these
events and found that the weights assigned to the risk factors included
in the Framingham risk function are different for both. By separately esti-
mating the hazards of these events, discrimination increased only very
little, whereas calibration improved substantially compared to predicting
CVD as a combined endpoint. The major contributor to CVD, being either
CHD or stroke, differed between individual risk proﬁles, as illustrated by
the four examples. This can have important clinical implications for the
allocation of preventive interventions. For example, aspirin is currently
recommended in men with a high risk of CHD, while in women the
recommendation is only made for those with a high risk of stroke [11].
As we treated CHD, stroke and non-CVD as competing events, our
risk function provides information on the separate events and also al-
lows for adding the separate risks of CHD and stroke to obtain an esti-
mate of total CVD risk. This provides clinicians with additional
information beyond a risk function which estimates CVD as a single
endpoint or separate models for CHD and stroke which do not account
for competing risks. Secondly, treatment beneﬁts of preventive inter-
ventions such as cholesterol-lowering drugs can be more precisely esti-
mated by applying the different risk reductions for CHD and stroke
separately instead of applying the overall reduction on CVD. Further im-
provement in the prediction of CVD could be obtained by
subcategorizing CHD and stroke in fatal and non-fatal events, ischemic
and non-ischemic events in the case of stroke, andmyocardial infarction
and heart failure in the case of CHD.
In conclusion, Framingham CVD risk predictions performwell in the
low- to intermediate risk categories in the Rotterdam Study. Recalibra-
tion is necessary as the Framingham function overestimates CVD risk in
the higher risk strata of the Rotterdam Study population. Disentangling
CVD into CHD and stroke separately provides additional information
about the individual contribution of CHD and stroke to total individual
CVD risk and provides clinicians with additional information about the
relative contribution of CHD and stroke.
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